MRE-269
CAS: 475085-57-5
Ref. TM-T3S2007
| 5mg | 51.00 € | ||
| 10mg | 87.00 € | ||
| 25mg | 140.00 € | ||
| 50mg | 187.00 € | ||
| 100mg | 314.00 € | ||
| 1mL*10mM (DMSO) | 57.00 € |
Estimated delivery in United States, on Tuesday 11 Mar 2025
Product Information
Name:
MRE-269
Synonyms:
- MRE269
- ACT-333679
- Acetic acid, [4-[(5,6-diphenylpyrazinyl)(1-methylethyl)amino]butoxy]-
- MRE 269
- Acetic acid, 2-[4-[(5,6-diphenyl-2-pyrazinyl)(1-methylethyl)amino]butoxy]-
- 2-[4-[(5,6-Diphenyl-2-pyrazinyl)(1-methylethyl)amino]butoxy]acetic acid
- ACT 333679
Description:
MRE-269 (ACT-333679) is an orally available and long-acting prostacyclin receptor agonist prodrug, used for the treatment of pulmonary arterial hypertension.
Notice:
Our products are intended for lab use only. For any other use, please contact us.
Brand:
Targetmol
Long term storage:
Notes:
Chemical properties
Molecular weight:
419.52
Formula:
C25H29N3O3
Purity:
99.57%
Color/Form:
Solid
MDL:
Melting point:
Boiling point:
Flash point:
Density:
Concentration:
EINECS:
Merck:
HS code:
Technical inquiry about: TM-T3S2007 MRE-269
Please use instead the cart to request a quotation or an order
If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.
